This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2005 Aug 1;23(22):4847-9.

doi: 10.1200/JCO.2005.03.903. Epub 2005 Jun 27.

Aromatase inhibitors and bone loss: risks in perspective

Charles L Shapiro

PMID: 15983395
DOI: 10.1200/JCO.2005.03.903

Editorial

Aromatase inhibitors and bone loss: risks in perspective

Charles L Shapiro. J Clin Oncol. 2005.

. 2005 Aug 1;23(22):4847-9.

doi: 10.1200/JCO.2005.03.903. Epub 2005 Jun 27.

Author

Charles L Shapiro

PMID: 15983395
DOI: 10.1200/JCO.2005.03.903

No abstract available

PubMed Disclaimer

Comment on

Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.
Lønning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Paolini J, Polli A, Massimini G. Lønning PE, et al. J Clin Oncol. 2005 Aug 1;23(22):5126-37. doi: 10.1200/JCO.2005.07.097. Epub 2005 Jun 27. J Clin Oncol. 2005. PMID: 15983390 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.